Shenzhen Capital Group

Shenzhen Capital Group Co., Ltd (SCGC) is a venture capital firm founded in 1999 by the Shenzhen Government. The company is dedicated to fostering national industries, developing national brands, and promoting economic transformation through investments in emerging sectors. SCGC primarily targets small to medium enterprises and innovative high-tech companies, focusing on those in various stages of growth, including startups and those undergoing transformation. Its investment portfolio spans industries that align with national policy support, such as information technology, internet services, new media, biopharmaceuticals, new energy, environmental protection, chemical engineering, and high-end equipment manufacturing. With a registered capital of 5.42 billion RMB and significant assets under management, SCGC has established itself as a leader in the venture capital landscape, having invested in numerous companies, many of which have achieved public listings across global capital markets.

Fang Aihua

Investment Director

Huang Tianxiang

Investment Director

Haitao Jin

Chairman

Lin Yunyu

Investment Director

Luo Xingqiang

Deputy General Manager

Zhang Yuhao

Senior Investment Manager

Zhou Songgan

Investment Manager

Ding Zuo

Chairman

Past deals in Medical Devices

Sheng Prius

Series A in 2025
Shengpu Ruisi focuses on the research and development of x-ray sources and high voltage power supplies.

Neomodulus

Series C in 2025
Nuoyimeier is a developer of implantable consumables.

Hannuo Medical

Venture Round in 2024
Hannuo Medical is a medical technology company that specializes in the development of high-end medical devices for critical extracorporeal life support.

Themis Medical

Series A in 2023
Themis Medical provides comprehensive solutions for medical beauty diagnosis and treatment. It offers full medical and aesthetic department solutions, including ultrasound, radio frequency, optics, and skin detection.

3N Tech

Series B in 2023
3N Tech is a manufacturer specializing in contact lens care products designed to enhance eye health. The company utilizes advanced biotechnology, specifically biomedical electrophoresis deproteinization technology, to create a range of solutions for contact lens users. Their product offerings include methods for protein precipitation removal, sterilization, antibacterial treatment, and safe storage of contact lenses. By focusing on these innovative technologies, 3N Tech aims to provide effective safety protection for contact lens users, ensuring that they can maintain healthy eyes while using their products.

Shengnuo Medical

Seed Round in 2023
Sono Medical is a biomedical technology company that focuses on R&D, design, production and sales of edical equipment in the field of cardiovascular diseases.

Puncture Robotic

Series A in 2023
Puncture Robotic is a developer of advanced venipuncture robots that facilitate automated blood collection and soft tissue interventions. The company's technology focuses on real-time image navigation to enhance precision in procedures such as percutaneous puncture for thoracoabdominal and pelvic tumors, as well as applications in medical aesthetics. Aiming to support medical institutions, Puncture Robotic provides intelligent and cost-effective robotic solutions that improve operational efficiency and patient care by enabling blood collection and other interventions without the need for human involvement.

Bite Micro

Series A in 2023
Better Micro Medical is a medical device company that is characterized by intervention and non-implantation, and offers doctors with comprehensive solutions in the field of peripheral vascular and structural heart disease.

Svision

Series C in 2023
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment.

Hairuisi Automation Technology

Series A in 2023
Hairuisi engages in the development, manufacture, and sale of airtightness detectors and inspection tools. The products are air tightness testers, auxiliary tooling for air tightness testing, and non-standard custom assembly equipment Their products are used in communication digital, audio, electrical, security, lighting, vehicle electronics, medical instruments, wire connections, and mobile phone columns.

Huaquejing Medical

Series A in 2023
Huaquejing Medical has developed a series of intelligent rehabilitation robots. They offer products that include upper-limb rehabilitation robots, finger rehabilitation robots, and cognitive rehabilitation robots. They provide services for the hospital and the family, from early rehabilitation intervention to sub-health prevention, from children's cognitive impairment to elderly limb disability.

Rosenbot

Series B in 2022
Rosenbot provides medical robot technology and uses technological innovation to promote the reform of medical models. It is committed to creating a new generation of orthopedic surgery robot systems with intelligent fracture reduction functions, it is the first in the world to realize advanced technologies such as intraoperative real-time 3D navigation, assisted fracture reduction operation, automatic operation planning, etc. The intelligent surgical operation of the whole operation process meets the urgent needs of clinical treatment.

Fremont Micro Devices

Venture Round in 2022
Fremont Micro Devices is a chip design company that specializes in the development of integrated circuits, particularly microcontroller chips, power management chips, and memory chips. Operating under a fabless business model, the company not only provides design services but also has independent development capabilities for semiconductor devices and related processes. Its products cater to various industries, including smart home technologies, consumer appliances, mobile office solutions, wearable devices, digital peripherals, audio-visual entertainment, and medical equipment. Fremont Micro Devices aims to deliver high-quality domestic chips that meet the needs of its diverse customer base.

MicroPort (Shanghai)

Post in 2022
MicroPort (Shanghai) is a prominent developer, manufacturer, and marketer of advanced medical devices in China, primarily focusing on minimally invasive products for treating vascular diseases. Established in May 1998, the company specializes in a range of cardiovascular and diabetes devices, with its flagship product being a second-generation cobalt-chromium alloy drug-eluting stent. Additionally, MicroPort produces various vascular stent-grafts designed for addressing vascular conditions, as well as innovative stents for applications in the brain and other surgical contexts. The company's products have been utilized in over 1,100 hospitals across China and are exported to more than 20 countries in regions such as Asia Pacific (excluding China), South America, and Europe. MicroPort is committed to enhancing healthcare outcomes through its cutting-edge medical technologies.

Boston Micro Fabrication

Series C in 2022
Boston Micro Fabrication is a micro-scale 3D printing system manufacturer dedicated to the development of micro-scale 3D printing systems and functional composites. used in microfluidics, medical devices, electronics, and education.

Kai Medtech

Series B in 2022
Kai Medtech is a company that specializes in the development and supply of medical devices aimed at treating cerebrovascular diseases. It operates as a marketing and sales entity within the vascular intervention medical device sector, emphasizing the use of nerve intervention techniques. Committed to innovation, Kai Medtech integrates research and development with production and marketing to create comprehensive solutions that enhance patient care in the treatment of cerebrovascular and neurological conditions. The organization aims to establish itself as a leader in the vascular device industry by focusing on advanced neurointerventional technology.

OrbusNeich Medical

Series B in 2021
OrbusNeich Medical is a global leader in vascular intervention solutions. It offers an extensive range of products that set industry standards.

JH Cispoly

Seed Round in 2021
JH Cispoly specializes in the development of diagnostic technology and equipment specifically aimed at the early detection of gynecological tumors. The company focuses on innovative solutions for identifying ovarian, cervical, and endometrial cancers, among others. By enhancing the capabilities for early diagnosis, JH Cispoly plays a crucial role in improving patient outcomes through timely intervention in gynecological health.

YuanHua Zhineng

Series A in 2021
YuanHua Zhineng specializes in sophisticated medical and intelligent service robots. The company provides a robot system for orthopedic surgery that can help surgeons with a variety of procedures, including spine, knee/hip replacement, trauma, and knee/hip replacement.

TytoCare

Series D in 2021
TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

Cryofocus Biotech

Series B in 2021
Cryofocus Biotech is a Shanghai-based cryoablation device manufacturer, focusing on the application of cryogenic technology in the field of cardiovascular interventional therapy.

Sino Vision

Series D in 2020
SinoVision is a medical device manufacturing company based in China, established in 2012. It specializes in the development of computed tomography (CT) scanners, offering a range of products including 16-Slice, 32-Slice, and 64-Slice CT scanners. The company also provides advanced technologies such as the sROBOT robot CT navigation system and sAI intelligent imaging solutions. SinoVision holds intellectual property for CT detectors and designs X-ray tubes and high-voltage power supplies specifically for CT scanners. Additionally, it operates a cloud diagnosis platform that integrates CT image post-processing workstations with an online consultation platform, facilitating comprehensive imaging diagnoses for healthcare professionals and institutions.

Shanghai Horizon Medical Technology

Venture Round in 2020
Shanghai Horizon Medical Technology focuses on medical solutions its business covers the R&D, manufacturing, marketing, and technical support of products at every step of the ART treatment process, including egg and sperm collection, fertilization, embryo culture, cryopreservation, and embryo transfer. It was founded in 2018 and headquartered in Shanghai, China.

Igenesis

Series C in 2020
Igenesis is a manufacturer of molecular diagnostic technology and products. They focus on real-time molecular diagnostic technology and have developed a series of automated detectors, reagents, reagent smart boxes, and supporting equipment for microbial detection, personalized drug genetic testing, cancer detection, forensic evidence, food safety, and other fields.

Remegen

Private Equity Round in 2019
Remegen is a Chinese biopharmaceutical company focused on developing novel biologics, primarily monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), to address unmet medical needs in life-threatening conditions. Headquartered in Yantai with labs/offices in Beijing and California, Remegen's portfolio includes Telitacicept for systemic lupus erythematosus and Disitamab Vedotin for various cancers.

Hrain Biotechnology

Series B in 2019
Hrain Biotechnology is a developer of tumor immunotherapy technologies focused on delivering precise treatments for cancer patients. The company employs Chimeric Antigen Receptor T-cell (CAR-T) technology to enhance the effectiveness of cancer therapies. By establishing clinical trial platforms in various locations, including Beijing, Jiangsu, Chongqing, and Henan, Hrain Biotechnology facilitates the development and implementation of innovative medical treatments in clinical settings. Through its research and technology, the company aims to improve patient outcomes by enabling hospitals and clinics to offer advanced therapeutic solutions tailored to individual needs.

RAYSEES

Seed Round in 2019
RAYSEES (Shenzhen) Co., Ltd. is a high-tech company based in Shenzhen, China, specializing in the research, development, and manufacturing of optoelectronic chips and devices. The company focuses on providing semiconductor light source solutions for various applications, including face and iris recognition, assisted driving, security monitoring, and spectral analysis. With a team that possesses extensive technical expertise and experience in product industrialization, RAYSEES aims to deliver industry-leading light source products and competitive optical solutions. Its innovations cater to diverse sectors such as artificial intelligence, identification, 3D vision, smart logistics, health monitoring, and special lighting.

Fanmi Cloud

Series A in 2019
Fanmi Technology Limited, based in Chengdu, China, specializes in the research and development of intelligent maternal and baby health products. With six years of experience in creating professional medical products, the company is dedicated to delivering safe and reliable solutions for infant care. Its product range includes innovative items such as a chip for excreta identification and analysis, an intelligent thermometer for forehead temperature detection, and a toilet test solution. Fanmi Technology aims to leverage advanced technology to enhance the well-being of mothers and their children.

Lidakang Technology

Series A in 2019
Beijing Lidakang Technology Co., Ltd., established in 1998, specializes in the manufacturing and distribution of surgical implants. Its product portfolio includes artificial joint systems for hips, knees, and bone tumors, crafted from materials like microporous titanium alloy. These high-quality implants are designed to meet the needs of healthcare professionals and improve patient outcomes.

MabPlex

Series A in 2019
MabPlex International Ltd is a contract development and manufacturing organization specializing in biopharmaceuticals, including monoclonal antibodies, recombinant proteins, antibody-drug conjugates, and bispecifics. Founded in 2013, the company operates from its headquarters in Yantai, China, and has an additional office in Fremont, California. MabPlex provides a comprehensive range of services that encompass all stages of drug development, from DNA to finished drug products. Its offerings include customized mammalian cell medium, cell banking, and the manufacturing of monoclonal antibody active pharmaceutical ingredients, as well as fill and finish services for biologics and antibody-drug conjugates. The company aims to deliver high-quality solutions for bio-manufacturing to its global partners.

TytoCare

Series C in 2019
TytoCare develops handheld devices and software that enable users to perform self-examinations, facilitating remote diagnosis by healthcare professionals. The company's tools allow examination of various body areas and diagnose common conditions. TytoCare offers solutions for consumers (TytoHome), professionals (TytoPro), and remote clinics (TytoClinic). Incorporated in 2011, the company is headquartered in Netanya, Israel with an additional office in New York.

Chishine Optoelectronics

Series A in 2019
Xi'an Chishine Optoelectronics Technology Co., Ltd. is a high-tech enterprise based in China that focuses on 3D digitization and intelligent hardware development. With over a decade of experience in 3D technology, the company has created advanced 3D imaging and artificial intelligence solutions, including high-precision 3D depth camera technology. These innovations can be integrated into various products such as mobile phones, computers, and robots, finding applications in diverse sectors including home entertainment, medical plastic surgery, military security, cultural industries, maker education, and industrial testing. Chishine has built an extensive 3D face model library, featuring the world's largest high-precision 3D Chinese face dataset. This resource supports the development of cutting-edge 3D artificial intelligence algorithms, enabling advancements in 3D face recognition and gesture interaction, and positioning the company to enter emerging markets such as consumer electronics and high-level security.

Frontier Biotechnologies

Series C in 2017
Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company headquartered in Nanjing, China, specializing in the discovery, development, and manufacturing of innovative medicines aimed at improving patient health. Founded in 2013, the company addresses unmet medical needs primarily in anti-HIV treatment and pain management. Its notable products include Aikening, a long-acting HIV fusion inhibitor, and AB001, a transdermal patch designed for musculoskeletal joint pain relief. Additionally, the company is developing a combination regimen of Albuvirtide and 3BNC117, a monoclonal antibody targeting HIV-1 viruses. Frontier Biotech's commitment to excellence spans the entire development cycle, from drug discovery to global clinical trials, with multiple candidates currently in Phase I and Phase II trials in both China and the United States. The company's focus on long-acting therapies and differentiated products positions it as a competitive player in the biopharmaceutical industry.

SHENZHEN C.K.J STOMATOLOGICAL HOSPITAL

Series A in 2016
SHENZHEN C.K.J STOMATOLOGICAL HOSPITAL offers services for oral diagnostics and treatment. Concentrating on oral disciplines, there are oral implantology, orthodontics, prosthodontics, endodontics, periodontics, children's stomatology, oral prophylaxis, and oral and maxillofacial surgery.

BOZWIN

Series B in 2016
BOZWIN is engaged in the research and development, production, and sales of medical imaging products. They provide general imaging services in different scenarios, including routine outpatient clinics, fever clinics, emergency centers, physical examination centers, radiotherapy centers, and inpatient buildings.

Medcaptain

Angel Round in 2016
Medcaptain develops and provides medical instruments and related services across infusion management, in-vitro diagnostics, and rehabilitation care, with additional offerings in medication delivery, anesthesia and respiratory care. The company focuses on innovation in medical instruments and aims to supply local, innovative solutions to healthcare providers, supporting access to high-quality medical products and services. It also pursues corporate social responsibility by creating jobs and contributing to societal value.

JHOME

Post in 2015
JHOME is an import and export rights company and an Internet B2C sales platform for drugs and medical devices. Their production and sales of in vitro diagnostic reagents and instruments, medical imaging, and medical electronic equipment. They focus on product and technological innovation in the fields of medical care, family health, and public safety.

Genrui Biotech

Angel Round in 2015
Genrui Biotech Inc., formerly known as Shenzhen Genius Electronics Co., Ltd, is a prominent Chinese company established in 2004 that specializes in the development, manufacturing, and marketing of in vitro diagnostic (IVD) equipment and reagents. The company offers a diverse product range that includes immunoassay, chemistry, hematology, urinalysis, and point-of-care diagnostics, alongside related reagents. Genrui has made significant strides in product innovation and has expanded its market presence, serving customers not only throughout China but also in over 100 countries globally. The company is committed to providing high-quality IVD medical products to healthcare practitioners.

Genrui Biotech

Series A in 2014
Genrui Biotech Inc., formerly known as Shenzhen Genius Electronics Co., Ltd, is a prominent Chinese company established in 2004 that specializes in the development, manufacturing, and marketing of in vitro diagnostic (IVD) equipment and reagents. The company offers a diverse product range that includes immunoassay, chemistry, hematology, urinalysis, and point-of-care diagnostics, alongside related reagents. Genrui has made significant strides in product innovation and has expanded its market presence, serving customers not only throughout China but also in over 100 countries globally. The company is committed to providing high-quality IVD medical products to healthcare practitioners.

WUHAN YOUNGSEN BIOTECH CO.

Series A in 2014
Wuhan Yangsen Biotechnology is a technology company that focuses on research and development, production and sales of medical devices. Their product such as three-layer bionic structure artificial blood vessel that is designed with reference to the human body's own arterial structure, which greatly optimizes the artificial blood vessel product.

Xierkang

Venture Round in 2013
Xierkang (希尔康血液) is a Chinese high-tech enterprise engaged in the research and development, production, and clinical research of blood purification equipment. The company has committed itself to the research and production of blood hemoperfusion apparatus. Its product portfolio includes six domains of resin adsorption column, resin carbon adsorption column, bilirubin adsorption column, low density cholesterol protein adsorption column, endotoxin adsorption column, and specific adsorption column. Xierkang is focused on the development of hemoditoxifier, and owns the proprietary intellectual property rights for its raw material synthesis, specialized equipment production, and tank body design.

Fenghui Yixue

Angel Round in 2010
Fenghui Yixue is engaged in independent clinical biochemical reagent research, development, production, and sales. is an elevated company that produces medical devices. In addition to other functional departments, there is a marketing company, a research and development department, a production department, and a quality inspection department, among others.

Micropoint Bio

Angel Round in 2009
MicroPoint Bioscience, Inc. is a Chinese company focused on the research and development of biochips. It specializes in the manufacturing of point-of-care testing (POCT) equipment and biological diagnostic test reagent cards, primarily for medical applications. The company's Lab On a Chip product series leverages micro-electronic mechanical systems (MEMS) to offer advanced microfluidic bio-diagnostic testing solutions. These innovations facilitate early diagnosis and monitoring of critical health issues, including vascular diseases and tumors. MicroPoint Bioscience customizes its products and services to meet the needs of various sectors, including human health, environmental protection, food safety, and scientific research, thereby contributing to improved healthcare outcomes and operational efficiency in medical settings.

Guojia New Materials

Series A in 2009
Zhuhai Guojia New Macromolecule Material Co., Ltd. is the first domestic enterprise which professionally engages in the production and sales of gel core material and applied gel core products. The gel technology of the company covers many fields, such as agriculture and forestry, environmental protection, medicine, daily chemicals, and so on. And it owns core technologies and intellectual properties in every field, which have a broad range of applications, good market prospects, and great scientific and technological contentssupport. It is a national-level high-tech enterprise that assembles several high quality resources, such as Wuhan University, China University of Geosciences, the Institute of Chemistry of the Chinese Academy of Sciences, Shenzhen Capital Group Co., Ltd. and so on. The main business of Guojia New Materials is the research, production and sales of core materials of gel, medical gel, applied core products of environment-friendly gel and service for environmental protection technology of heavy metal and sludge.

Glory Medical

Series C in 2009
Shenzhen Glory Medical Co., Ltd. specializes in integrated solutions for hospital construction and management in China. Founded in 1998 and headquartered in Shenzhen, the company offers a comprehensive range of services including hospital system analysis, planning, and medical engineering. Additionally, Glory Medical is involved in the design, decoration, and construction of hospital buildings, as well as the research, development, and production of medical equipment and facilities. The company provides one-stop services encompassing preliminary consulting, project financing, operation, maintenance, and logistics management. Glory Medical also markets medical equipment and consumables while maintaining a robust distribution and service network through various subsidiaries and branch offices across China.

MicroPort (Shanghai)

Series C in 2002
MicroPort (Shanghai) is a prominent developer, manufacturer, and marketer of advanced medical devices in China, primarily focusing on minimally invasive products for treating vascular diseases. Established in May 1998, the company specializes in a range of cardiovascular and diabetes devices, with its flagship product being a second-generation cobalt-chromium alloy drug-eluting stent. Additionally, MicroPort produces various vascular stent-grafts designed for addressing vascular conditions, as well as innovative stents for applications in the brain and other surgical contexts. The company's products have been utilized in over 1,100 hospitals across China and are exported to more than 20 countries in regions such as Asia Pacific (excluding China), South America, and Europe. MicroPort is committed to enhancing healthcare outcomes through its cutting-edge medical technologies.

MicroPort (Shanghai)

Series B in 2002
MicroPort (Shanghai) is a prominent developer, manufacturer, and marketer of advanced medical devices in China, primarily focusing on minimally invasive products for treating vascular diseases. Established in May 1998, the company specializes in a range of cardiovascular and diabetes devices, with its flagship product being a second-generation cobalt-chromium alloy drug-eluting stent. Additionally, MicroPort produces various vascular stent-grafts designed for addressing vascular conditions, as well as innovative stents for applications in the brain and other surgical contexts. The company's products have been utilized in over 1,100 hospitals across China and are exported to more than 20 countries in regions such as Asia Pacific (excluding China), South America, and Europe. MicroPort is committed to enhancing healthcare outcomes through its cutting-edge medical technologies.

Anke

Series A in 2000
Shenzhen Anke Hi-Tech Co., Ltd. is a high-tech enterprise based in Shenzhen, China, specializing in the research, development, manufacturing, and servicing of advanced medical equipment. The company produces a wide range of products, including MRI, CT, X-ray, and ultrasound systems, as well as devices for orthopedics and neurosurgery. Anke has established itself as a pioneer in the Chinese market, being the first to manufacture various medical technologies such as MRI and color ultrasonography. Its operations also encompass medical informatics and therapeutics, addressing the needs of both domestic and international customers. Founded in 1986 and originally known as Analogic Scientific, Inc., the company rebranded in 2001 to reflect its focus on high-tech medical solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.